Trials For Preparation Of Combined Vaccine Of Equine Influenza, Equine Herpesvirus–1, Rabies Virus And Tetanus Toxoid

Document Type : Original Article

Authors

1 Department of Equine Vaccine Research, Veterinary Serum and Vaccine Research Institute (VSVRI), Abbassia, Cairo, Agriculture Research Center (ARC), Egypt.

2 Department of Sera and antigens Research , Veterinary Serum and Vaccine Research Institute (VSVRI), Abbassia, Cairo, Agriculture Research Center (ARC), Egypt.

3 Department of In-House Quality Control , Veterinary Serum and Vaccine Research Institute (VSVRI), Abbassia, Cairo, Agriculture Research Center (ARC), Egypt.

4 Department of Pet Animal Vaccine Research, Veterinary Serum and Vaccine Research Institute (VSVRI), Abbassia, Cairo, Agriculture Research Center (ARC), Egypt.

Abstract

A combined vaccine of Equine influenza (EI), equine herpesvirus–1 (EHV-1), rabies virus and tetanus toxoid adjuvanted with saponin and Alhydrogel was prepared. Quality control testing of such vaccine revealed that it was free from foreign contaminants, safe for Guinea-pigs, mice and mares. It was inoculated into Guinea -pigs as a preliminary evaluation for its potency and it was proven safe and potent. Also, it exceeded the permissible protective level allowed to be used for the vaccination of horses. Two groups of mares were used for evaluating the potency of the vaccine. The first one received two doses (5 ml) of the prepared vaccine with 4 weeks interval while the 2nd group was kept without vaccination as control. The mean haemagglutination inhibition (HI) influenza antibody titer reached its maximum at the 2nd month post-vaccination (MPV); 2048 while EHV-1 antibodies reached the peak at the 3rd MPV as recorded by ELISA and neutralizing indices; 1790 and 3.50. Rabies antibodies were detectable in vaccinated mares by the 2nd week post-vaccination showing titers of 16 and 1.0 by serum neutralization test (SNT) and ELISA, respectively recording their peaks (128 by SNT and 2.15 by ELISA) at the 2nd MPV. Tetanus antitoxic titer increased till reaching the peak at the 2nd MPV (40IU/ml) as determined by toxin neutralization test. Depending on these results, it could be concluded that the prepared inactivated EI, EHV-1, rabies and tetanus vaccine is safe and potent for mares providing them with good protective levels of specific antibodies against the 4 used antigens up to not less than 6 months.

Keywords

Main Subjects

References

ABDELHADY, H. A. 2016.Preparation of inactivated EHV-1 with different adjuvants. Ph.D. Thesis; Immunology, Fac. Vet. Med. Alexandria Univ.
ALBEHWAR, A.M. 2009.Studies on prophylactic and emergency vaccination of farm animals against rabies; Ph. D. Thesis (Infectious Diseases) Fac. Vet. Med. Cairo Univ.
ALLEN, G.P. AND BRYANS, J.T. 1986.Molecular epidemiology, pathogenesis and prophylaxis of equine herpesvirus-1 infections.In: Progress in Veterinary Microbiology and Immunology, Vol. 2, Pandey R., ed. Karger, Basel, Switzerland & New York, USA, 78–144.
BANNAI, H., MAE, N., ODE, H. ET AL. 2014. Successful control of winter pyrexias caused by equine herpesvirus type 1 in Japanese training centers by achieving high vaccination coverage. Clinical and Vaccine Immunology, 21(8), 1070-1076.‏
BAYUMI, M., MOUSTAFA, A., MADKOUR, N., SELIM, A. AND ABDELAZIZ, W. 2018a. Trial for Preparation of Combined Equine Influenza virus, Equine Herpesvirus-1 and Tetanus Toxoid Vaccine. Benha Veterinary Medical Journal, 34(1), 106-116.‏
BAYOUMI, M., SELIM, A., MOUSTAFA, A. M., MADKOUR, N. K. AND EL-HELW, H. A. 2018b. Field Evaluation of the prepared combined equine influenza, equine herpesvirus-1 and tetanus toxoid vaccine in horses. Benha Veterinary Medical Journal, 34(1), 289-299.‏
BRITISH VET. PHARMACOPOEIA (EDS) 2009.Clostridium tetani vaccines (Veterinary Suppl.), p. 233 ISBN: 9780113227990.
BRÜGGEMANN, H., BÄUMER, S., FRICKE, W. F. ET AL. 2003. The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proceedings of the National Academy of Sciences, 100(3), 1316-1321.‏
CULLINANE, A. AND NEWTON, J. R. 2013. Equine influenza—a global perspective. Veterinary Microbiology, 167(1-2), 205-214.‏
DALIA, H.N. 2017. Study the effect of different adjuvants on inactivated equine herpes virus – 1 vaccine. M.Sc. Virology, Fac. Science, Azher. Uni.
DAVISON, A.J. 2002. Evolution of the herpesviruses. Vet Microbiol 86:69–88
EDRIES, S. M., AMANI, A. S., ALBEHWAR, A. M., & HEMMET, E. S. S. 2017. Improvement of inactivated rabies vaccine using montanide pet gel-A. Benha J. Appl. Sci.(BJAS), 2(1), 145-149.‏
EIAKA, A.M.E. 2017. Virological and immunological studies on the effect of bee venom on rabies virus. Ph. D. Thesis (Virology) Fac. Vet. Med. Benha Univ.
Gildea, S., Sanchez Higgins, M. J., Johnson, G., Walsh, C. and Cullinane, A. 2016. Concurrent vaccination against equine influenza and equine herpesvirus–a practical approach. Influenza and other respiratory viruses, 10(5), 433-437.‏
GUO, P., GOEBEL, S., DAVIS, S. ET AL. 1989. Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gpl3 and protection of immunized animals. Journal of Virology 63, 4189-4198.
GUPTA, R.K., MAHESHWARI, S. C. AND SINGH, H. 1985. The titration of tetanus antitoxin IV.Studies on the sensitivity and reproducibility of the toxin neutralization test. Journal of Biological Standardization, 13, 143-149.
HELDENS, J.G., KERSTEN, A.J., WESTSTRATE, M.W. AND VAN DEN HOVEN, R. 2001. Duration of immunity induced by an adjuvanted and inactivated equine influenza, tetanus and equine herpesvirus 1 and 4 combination vaccine. Vet Q. ;23(4):210-7.
HELDENS, J.G., VAN DE WOUW, J.C.A. AND VAN LOON, A.A.W. 2002. An updated equine influenza vaccine and an equine influenza herpesvirus combinationvaccine containing an Immunostimulant adjuvant provoke equal young foals throughout the primary vaccination course. Vet. J. 164, 288–291.
HELDENS, J.G., POUWELS, H.G., DERKS, C.G., VANDEZANDE, S.M. AND HOEIJMAKERS, M.J. 2010. Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOH-Matrix. Vaccine. 8: 28 (43): 6989-96.
KHODIER,  M.H. 1999. Studies on vaccination of farm animals (cattle, horse, sheep) in addition to dogs and cats with inactivated tissue culture rabies vaccine; Beni-Suif Vet.Med.J.;9 (3-A): 111-120.
KHODEIR, M. H. AND DAOUD, A.M. 2008. Preparation of anti-rabies hyperimmune serum for emergency Immunization of farm animals; 4th Int. Sci. Conf. NRC, 1-9.
KHUSRO, A., AARTI, C., RIVAS-CACERES, R. ET AL. 2020. Equine herpesvirus-I infection in horses: Recent updates on its pathogenicity, vaccination, and preventive management strategies. Journal of Equine Veterinary Science, 87, 102923.‏ https://doi.org/10.1016/j.jevs.2020.102923
LAABASSI, F., LECOUTURIER, F., AMELOT, G. ET AL. 2015. Epidemiology and genetic characterization of H3N8 equine influenza virus responsible for clinical disease in Algeria in 2011.Transbound.Emerg. Dis. 62, 623–631. http://dx.doi.org/10.1111/tbed.12209.
LINDBLAD, E.B. 2004. Aluminum adjuvantsin retrospect and prospectVaccine, 22, 3658-3668.
MAGDA, A. K., EMAN, M.E., NASHWA, K.M. ET AL. 2011. Characterization of Equine Influenza virus H3N8 isolated in Egypt in 2008’ Apologia (3):35-44.
MARTHA, L.L. AND CRAIG, J.P. 1997. Clostridium tetani: immune response and diagnostic methods, In Manual of clinical laboratory immunology, Fifth edition, ASM press, Washington, D.C.
MESQUITA, A.L.P., ANDRESSA, F.A., DENNIS, A. ET AL.2017. Equine herpesvirus type 1 induces both neurological and respiratory disease in Syrian hamsters. Vet. Microbiol., 203,117–124
NASHWA, K.M., EMAN, M.E., NEHAL, S.S., FATMA, F.Y., EL-KABBANY, M.M.A. AND SOLIMAN, I.M.A. 2016. Duration of immunity induced by combined vaccine against Equine influenza and Equine herpesvirus-1. VMJG, 62, 1110-1423.
OIE TERRESTRIAL MANUAL, 2018. Rabies (infection with rabies virus and other lyssaviruses). Chapter 3.1.17.578-612.
OIE TERRESTRIAL MANUAL, 2019a. Tests for sterility and freedom from contamination of biological materials. Chapter 1.1.9.
OIE TERRESTRIAL MANUAL, 2019b. Equine Influenza (Infection with equine influenza virus). Chapter 3.5.7, 1-19.
PAILLOT, R., MARCILLAUD, PITEL, C., D’ABLON, X., PRONOST,,S. 2017. Equine Vaccines: How, When and Why? Report of the Vaccinology Session, French Equine Veterinarians Association, 2016, Reims.
RAJPUT, Z.I., HU, S.H., XIAO, C.W. AND ARIJO, A.G. 2007. Adjuvant effects of saponins on animal immune responses. J. Zhejiang Univ. Sci. B. 8, 153–161
REED, L.J. AND MEUNCH, H. 1938. A simple method of estimating fifty per cent endpoints. Am.J.Epidemiol.  27 (3):493-497.
RIBEIRO, M.G., NARDI JÚNIOR, G.D., MEGID, J. ET AL. 2018. Tetanus in horses: An overview of 70 cases. Pesquisa Veterinária Brasileira, 38(2), 285-293.‏
ROSSITER, P.B., JESSETT, D.M. AND TAYLOR, W.P. 1985. Microneutralization system for use with different strains of peste des petits ruminants and rinderpest virus. Tropical Animal Health and Production 17:75–81.
RUSLI, N.D., MAT, K.B. AND HARUN, H.C. 2014. A review: interactions of equine herpesvirus-1 with immune system and equine lymphocyte. Open J Vet. Med., 4, 294.
SAFAA, A.W. AND HUSSIN, M.G. 2012. Immune response of horsesvaccinated with tissue culture inactivated EHV – 1 oil Montanide ISA70 adjuvanted vaccine. Egypt J. Agric, Res; 90(3), 1309 - 1321.
SCHWARZ, D. G., BARRETO, F. M., BRANCO, M.D.A. ET AL. 2020. Equine Rabies in the Southern Region of Piauí State. Acta Scientiae Veterinariae, 48.‏
SHANKAR, H. AND YADAV, M. P. 1986. Occurrence of paralytic syndrome inequines due to equine Herpes virus – 1 Rev. Sci, Tech, Off. Int. Epiz., 5 (1): 15-21
SLATER, I.D., GIBSON, J.S. AND FIELD, H.J. 1993. Pathogenicity of thymidine kinase - deficient mutant of EHV-1 in mice and specific pathogen free foals. J. Gen Virol., 74(5): 819-828.
SOLIMAN, I.M.A., EL-MENEISY, A.A., NASHWA,  K.M. ET AL. 2011.  Preparation of Combined Equine Influenza and Tetanus Toxoid vaccine. Veterinary Medical Journal Giza, 59, 353-363.
SUGIURA, T., KONDO, T., MATSUMURA, T. ET AL.1997. Evaluation of enzyme linked immunosorbent assay for titration of antibodies toEHV-1. J. Equine Sci., 8(3): 57-61.
WHO, 2018. Rabies vaccines and immunoglobulins: WHO position paper, April 2018.  https://www.who.int/news-room/fact-sheets/detail/EA9FC951-9CFF-4913-8D5D-95EE564F66B0
Journal of Applied Veterinary Sciences
Volume 6, Issue 1
January 2021
Pages 38-44

Files

History

  • Receive Date: 07 December 2020
  • Revise Date: 04 January 2021
  • Accept Date: 15 January 2021

Share

How to cite

Statistics